Medical device company Zimmer Biomet Holdings is demonstrating significant strides in biotech innovation. The company received CE Mark certifications for its RibFix Advantage® Fixation System and Persona® Revision Knee System in a strategic boost for its portfolio. Achievements in Q3 and Q4 2024 financial results were reported, coupled with a strong revenue growth highlighted during their Q3 2024 earnings call.
Zimmer Biomet announced the acquisition of Paragon 28, expanding their reach into the foot surgery market, while also securing FDA clearance for its OsseoFit™ Stemless Shoulder System, and Persona® Revision SoluTion™ Femur. However, stock performance has been subpar over the past five years, and a 23% loss was endured by shareholders.
Expectations for 2025 profits were below estimates, while stock trading also faltered. Notwithstanding, they continued their quarterly dividend of $0.24, and several changes to the company's board were unveiled, including the appointment of Arnold Schwarzenegger as Chief Movement Officer and Jehanzeb Noor as Senior VP, Chief Strategy, Innovation and Business Development Officer.
Zimmer Biomet Holdings ZBH News Analytics from Wed, 29 May 2024 07:00:00 GMT to Wed, 02 Apr 2025 14:05:15 GMT - Rating -2 - Innovation 7 - Information 8 - Rumor -1
